Protara Therapeutics, Inc. (TARA)
NASDAQ: TARA · Real-Time Price · USD
5.06
+0.07 (1.40%)
Apr 28, 2026, 4:00 PM EDT - Market closed
Protara Therapeutics Income Statement
Financials in millions USD. Fiscal year is January - December.
Millions USD. Fiscal year is Jan - Dec.
| FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
| Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
| Selling, General & Admin | 21.92 | 17.45 | 18.62 | 20.74 | 26.4 | |
| Research & Development | 42.63 | 31.7 | 24.99 | 16.81 | 21.09 | |
| Operating Expenses | 64.55 | 49.15 | 43.61 | 37.55 | 47.49 | |
| Operating Income | -64.55 | -49.15 | -43.61 | -37.55 | -47.49 | |
| Interest & Investment Income | 6.38 | 4.17 | 3.19 | 1.11 | 0.24 | |
| Other Non Operating Income (Expenses) | 0.73 | 0.39 | - | - | - | |
| EBT Excluding Unusual Items | -57.44 | -44.6 | -40.42 | -36.44 | -47.25 | |
| Impairment of Goodwill | - | - | - | -29.52 | - | |
| Pretax Income | -57.44 | -44.6 | -40.42 | -65.95 | -47.25 | |
| Net Income | -57.44 | -44.6 | -40.42 | -65.95 | -47.25 | |
| Net Income to Common | -57.44 | -44.6 | -40.42 | -65.95 | -47.25 | |
| Shares Outstanding (Basic) | 43 | 21 | 11 | 11 | 11 | |
| Shares Outstanding (Diluted) | 43 | 21 | 11 | 11 | 11 | |
| Shares Change (YoY) | 108.02% | 81.73% | 0.64% | 0.24% | 55.28% | |
| EPS (Basic) | -1.34 | -2.17 | -3.57 | -5.86 | -4.21 | |
| EPS (Diluted) | -1.34 | -2.17 | -3.57 | -5.86 | -4.21 | |
| Free Cash Flow | -56.46 | -35.87 | -37.6 | -26.58 | -35.1 | |
| Free Cash Flow Per Share | -1.32 | -1.74 | -3.32 | -2.36 | -3.13 | |
| EBITDA | -64.19 | -48.82 | -43.27 | -37.3 | -47.37 | |
| D&A For EBITDA | 0.36 | 0.33 | 0.34 | 0.25 | 0.12 | |
| EBIT | -64.55 | -49.15 | -43.61 | -37.55 | -47.49 | |
Source: S&P Capital IQ. Standard template.
Financial Sources.